Unfortunately, as COX-2 antagonists are usually accompanied with significant cardiovascular and gastrointestinal side effects, it will be necessary to identify new targets within the COX-2-mediated neuroinflammatory system to develop effective and safe therapeutic strategies for the treatment of depression. Here, PTGS2 is linked to depressive disorder.